Role of p21WAF1 and p27KIP1 in predicting biochemical recurrence for organ-confined prostate adenocarcinoma

Journal of the Chinese Medical Association

Volumn 70, Issue 1, 2007, Pages 11-15

  Wu, Tony Tong Lin ^a,b   Wang, Jyh Seng ^a,b   Jiaan, Bang Ping ^a   Yu, Chia Cheng ^a   Tsai, Jeng Yu ^a   Lin, Jen Tai ^a   Huang, Jong Khing ^a,b  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

p21; p27; Prognosis; Prostate neoplasms

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREDICTION; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION;

EID: 33846866228     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/S1726-4901(09)70294-1     Document Type: Article

References (24)

1. Rizzi DA. Medical prognosis - some fundamentals. Theor Med 1993;14:365-75.
2. Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, Gospadarowicz M, et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:995-1000.
3. Kuczyk M, Machtens S, Hradil K, Schubach J, Christian W, Knuchel R, Hartmann J, et al. Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients. Br J Cancer 1999;81:1052-8.
4. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. P21 is a universal inhibitor of cyclin kinases. Nature 1993; 366:701-4.
5. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
6. Michiei P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994;54:3391-5.
7. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor beta induces the cyclindependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 1995;92:5545-9.
8. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinase. Cell 1993;75:805-6.
9. Kawamata N, Seriu T, Koeffler HP, Bartram CR. Molecular analysis of the cyclin-dependent kinase inhibitor family: p16 (CDKN2/MTS1/INK4A), p18 (INK4C) and p27 (Kip1) genes in neuroblastomas. Cancer 1996;77:570-5.
10. WAF1) in normal and neoplastic prostate tissue. J Urol Pathol 1998;9:115-28.
11. WAF1 expression with disease-free survival and biochemical recurrence in prostate adenocarcinoma. Prostate 1999;40:256-60.
12. Aaltomaa S, Lipponen P, Eskelinen M, Ala-Opas M, Kosma VM. Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer. Prostate 1999;39:8-15.
13. Lacombe L, Maillette A, Meyer F, Veilleux C, Moore L, Fradet Y. Expression of P21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy. Int J Cancer 2001;95:135-9.
14. Wu TT, Hsu YS, Wang JS, Lee YH, Huang JK. The role of p53, bcl-2 and E-cadherin expression in predicting biochemical relapse for organ-confined prostate cancers in Taiwan. J Urol 2003;170:78-81.
15. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A. p27kip1, a cyclin-Cdk inhibitor links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994;8:9-22.
16. Erdamar S, Yang G, Harper JW, Lu X, Kattan MW, Thompson TC, Wheeler TM. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Mod Pathol 1999;12:751-5.
17. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, de Kernion JB, Loda M, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998; 159:941-5.
18. kip1 and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol 2000;164:2156-61.
19. kip1 protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 1997; 3:2269-74.
20. Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, et al. Loss of cyclin-dependent kinase inhibitor p27kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998;58:542-8.
21. Cote RJ, Shi Y, Groshen S, Feng AC, Cordon-Cardo C, Skinner D, Lieskovosky G. Association of p27kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 1998;90:916-20.
22. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995; 55:5187-90.
23. Byrne RL, Wilson Horne CH, Robinson MC, Autzen P, Apakama I, Bishop RI. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol 1997;79:190-5.
24. Cheville JC, Lloyd RV, Sebo TJ, Cheng L, Erickson L, Bostwick DG, Lohse CM, et al. Expression of p27kip1 in prostatic adenocarcinoma. Mod Pathol 1998;11:324-8.